Assessing the Impact of COVID-19 Patients Long Distance Transfers Between Intensive Care Units (TRANSCOV)

TRANSCOV Cohort. An Epidemiological Study Assessing the Impact of Critically Ill COVID-19 Patients Long Distance Transfers Between Intensive Care Units

The TRANSCOV cohort is a multicentre observational retrospective study aiming at assessing the health impact of extra regional transfers of critically ill COVID-19 patients.

Study Overview

• Status: Recruiting
• Conditions: Covid19
• Intervention / Treatment: Other: Inter ICU long distance patient transfer

Detailed Description

In spring 2020 four regions of France faced a surge of severe Coronavirus (COVID) patients which threatened to overflow local intensive care units (ICU) capacities. As an emergency response, between 03/13/2020 and 04/10/2020, an estimated 661 patients were transferred from overcrowded ICUs to other French regions and neighbouring countries. The study aims at assessing the impact of these inter-ICU transfers on the short and medium term physical and psychological outcomes in this population of severe COVID 19 patients.

All transferred patients between ICUs outside the origin region are invited to take part. For each transfer, up to four control patients will be selected among those admitted in the same ICU during the same period (+/-4 days of transfer date). Clinical data will be extracted from medical records and will include hemodynamic and respiratory parameters, as well as clinical severity scores before, during and after transfer. Data linkage with medico-administrative data will enrich the clinical database and allow follow-up up to one year after initial admission.

• Study Type: Observational
• Enrollment (Anticipated): 3060

Contacts and Locations

• Study Contact: Name: Olivier Grimaud, Ph.D., M.D; Phone Number: 33 02 99 02 28 34; Email: olivier.grimaud@ehesp.fr
• Study Contact Backup: Name: Christophe Fermanian, Ph.D.; Phone Number: 33 02 99 02 24 69; Email: christophe.fermanian@ehesp.fr

Study Locations

• France
  • Rennes, France, 35043
    • Recruiting
    • EHESP
    • Contact: Christophe Fermanian, Ph.D.; Phone Number: 33 02 99 02 24 69; Email: christophe.fermanian@ehesp.fr
    • Contact: Olivier Grimaud, Ph.D., M.D.; Phone Number: 33 02 99 02 2834; Email: olivier.grimaud@ehesp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Severely ill COVID-19 patients

Description

Inclusion Criteria:

• COVID-19 patients diagnosed biologically or by imaging
• Admission in ICU between 03/13/2020 and 04/10/2020

Exclusion Criteria:

• none

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Transferred group; The transferred group includes all severe COVID patients admitted in a French ICU ward and then transferred between the 03/13/2020 and 04/10/2020 to another ICU located outside the region of the initial ICU stay.	Other: Inter ICU long distance patient transfer; Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
Control group; The control group includes patients selected out of those whose entire ICU care has taken place in one of the hospitals which transferred patients. Up to 4 control patients will be selected for each transferred patient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survival	Status alive or dead	1 year

Collaborators and Investigators

• Sponsor: Ecole des Hautes Etudes en Santé Publique
• Investigators: Principal Investigator: Olivier Grimaud, Ph.D., M.D., Ecole des Hautes Etudes en Santé Publique

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2021
• Primary Completion (Anticipated): December 31, 2021
• Study Completion (Anticipated): December 31, 2022

Study Registration Dates

• First Submitted: June 16, 2021
• First Submitted That Met QC Criteria: June 16, 2021
• First Posted (Actual): June 18, 2021

Study Record Updates

• Last Update Posted (Actual): June 22, 2021
• Last Update Submitted That Met QC Criteria: June 17, 2021
• Last Verified: June 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: 20 CO 015 CZ

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No